Comment on: 'Eczematous drug eruption in patients with psoriasis under anti‐interleukin‐17A: does interleukin‐22 play a key role?'.

MLA

Li, Mengmeng, and Wei Li. “Comment on: ‘Eczematous Drug Eruption in Patients with Psoriasis under Anti‐interleukin‐17A: Does Interleukin‐22 Play a Key Role?’” Clinical & Experimental Dermatology, vol. 47, no. 12, Dec. 2022, p. 2305. EBSCOhost, https://doi.org/10.1111/ced.15386.

APA

Li, M., & Li, W. (2022). Comment on: “Eczematous drug eruption in patients with psoriasis under anti‐interleukin‐17A: does interleukin‐22 play a key role?” Clinical & Experimental Dermatology, 47(12), 2305. https://doi.org/10.1111/ced.15386

Chicago

Li, Mengmeng, and Wei Li. 2022. “Comment on: ‘Eczematous Drug Eruption in Patients with Psoriasis under Anti‐interleukin‐17A: Does Interleukin‐22 Play a Key Role?’” Clinical & Experimental Dermatology 47 (12): 2305. doi:10.1111/ced.15386.